Asia Pacific Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The Asia Pacific therapeutic vaccines market is projected to grow significantly, reaching approximately US$ 85,862.88 thousand by 2031, up from US$ 34,213.87 thousand in 2024, with an estimated compound annual growth rate (CAGR) of 14.0% from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccine market in the Asia Pacific region is witnessing robust growth, primarily fueled by advancements in technology and increased funding for vaccine research. Key players in this growth include China and India, which benefit from large populations, extensive immunization programs, and rising healthcare expenditures. Japan's advanced healthcare system and high vaccination rates also contribute significantly to market expansion. Furthermore, Australia is enhancing its market presence through strong government support and heightened public awareness regarding vaccination benefits.

Despite this growth, the market faces challenges such as stringent regulatory frameworks, high production and development costs, and limited awareness among patients and healthcare professionals. Addressing these challenges is crucial for the continued growth of the therapeutic vaccine sector in the Asia Pacific.

Market Segmentation Analysis

The therapeutic vaccines market can be segmented by product type, technology, and end user:

By Product: The market is divided into cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
By Technology: The market is categorized into allogenic and autologous vaccines, with allogenic vaccines leading in market share in 2024.
By End User: The end users include hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

The demand for innovative treatment options is driving significant investments and advancements in the therapeutic vaccines sector. The increasing number of clinical candidates progressing through various development stages is indicative of this trend. Innovative research and development in biotechnology are producing advanced therapeutic vaccines targeting a range of diseases, including chronic conditions like cancer and newer infections. For instance, Moderna's mRNA-4157 is currently in phase 2 trials, showing promise in combination with checkpoint inhibitors for melanoma treatment. The therapeutic vaccine pipeline is also expanding to address autoimmune diseases and infectious diseases such as HIV, HPV, and HBV.

Several companies are focusing on scientific and technical excellence to develop and launch new therapeutic vaccines. The expanding pipeline of vaccine candidates targeting diverse diseases presents significant opportunities to meet unmet medical needs. Below is a summary of notable therapeutic vaccine candidates:

ADXS11-001: A bacterial vector vaccine in Phase I/II for cervical carcinoma.
ISA101: A peptide/protein vaccine in Phase II for solid tumors.
NeoVax: A personalized peptide vaccine in Phase I for kidney cancer.
mRNA-4157: An mRNA-based neoantigen vaccine in Phase I/II for melanoma.
VGX-3100: A DNA vaccine in Phase I/II for cervical and head and neck cancers.
NASVAC: A virus-like particle vaccine in Phase III for HBV infection.
iHIVARNA: An mRNA vaccine in Phase I for HIV infection.

The ongoing clinical trials indicate a promising future for the therapeutic vaccines market, with new treatment options emerging to address unmet medical needs.

Country Insights

The Asia Pacific therapeutic vaccines market includes countries such as China, Japan, India, Australia, South Korea, and others. Australia is expected to maintain the largest market share in 2024, driven by its strong healthcare infrastructure and active involvement in vaccine development. Notably, Australian researchers have made significant progress in developing a therapeutic vaccine for Epstein-Barr virus (EBV), which could revolutionize treatment for diseases associated with EBV, including multiple sclerosis and certain cancers.

Additionally, South Australia is establishing itself as a leader in mRNA technology with the development of a state-of-the-art mRNA production facility, BioCina. This facility aims to enhance the production of therapeutic drugs and vaccines, supported by US$ 10 million in funding from the Australian government.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products.

Product Code: BMIRE00032092

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Asia Pacific Therapeutic Vaccines Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Prevalence of Chronic Conditions
- 4.1.2 Increasing Investments and Funding for Vaccine Development
4.2 Market Restraints
- 4.2.1 Regulatory Challenges
4.3 Market Opportunities
- 4.3.1 Extending Product Pipeline
4.4 Future Trends
- 4.4.1 Advancements in Vaccine Technology
4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - Asia Pacific Market Analysis

5.1 Asia Pacific Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
5.2 Asia Pacific Therapeutic Vaccines Market Forecast Analysis

6. Asia Pacific Therapeutic Vaccines Market Analysis - by Product

6.1 Cancer Vaccine
- 6.1.1 Overview
- 6.1.2 Cancer Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.2 infectious Disease Vaccine
- 6.2.1 Overview
- 6.2.2 infectious Disease Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.3 Others
- 6.3.1 Overview
- 6.3.2 Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. Asia Pacific Therapeutic Vaccines Market Analysis - by Technology

7.1 Allogenic Vaccine
- 7.1.1 Overview
- 7.1.2 Allogenic Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Autologous Vaccine
- 7.2.1 Overview
- 7.2.2 Autologous Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. Asia Pacific Therapeutic Vaccines Market Analysis - by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 Clinics
- 8.2.1 Overview
- 8.2.2 Clinics: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. Asia Pacific Therapeutic Vaccines Market - Country Analysis

9.1 Asia Pacific
- 9.1.1 Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.2.1 China: Asia Pacific Therapeutic Vaccines Market Share - by Product
    - 9.1.1.2.2 China: Asia Pacific Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.2.3 China: Asia Pacific Therapeutic Vaccines Market Share - by End User
  - 9.1.1.3 Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.3.1 Japan: Asia Pacific Therapeutic Vaccines Market Share - by Product
    - 9.1.1.3.2 Japan: Asia Pacific Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.3.3 Japan: Asia Pacific Therapeutic Vaccines Market Share - by End User
  - 9.1.1.4 India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.4.1 India: Asia Pacific Therapeutic Vaccines Market Share - by Product
    - 9.1.1.4.2 India: Asia Pacific Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.4.3 India: Asia Pacific Therapeutic Vaccines Market Share - by End User
  - 9.1.1.5 South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.5.1 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by Product
    - 9.1.1.5.2 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.5.3 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by End User
  - 9.1.1.6 Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.6.1 Australia: Asia Pacific Therapeutic Vaccines Market Share - by Product
    - 9.1.1.6.2 Australia: Asia Pacific Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.6.3 Australia: Asia Pacific Therapeutic Vaccines Market Share - by End User
  - 9.1.1.7 Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.7.1 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by Product
    - 9.1.1.7.2 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.7.3 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Therapeutic Vaccines Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Dendreon
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 BioNTech SE
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Serum Institute of India Pvt. Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck & Co Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Amgen Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 ISA Pharmaceuticals BV
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 INOVIO Pharmaceuticals Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Transgene SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 THERAVECTYS SA
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 CureVac SE
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms